Haisco Pharmaceutical Group Co., Ltd.
002653
Classifica tra le azioni
#2068
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Prezzo delle azioni
$8.74
Capitalizzazione di mercato
$9.97B
Variazione (1 giorno)
1.17%
Variazione (1 anno)
20.15%
Paese
CN
Scambia Haisco Pharmaceutical Group Co., Ltd. (002653)
Categoria
Healthcare
Utile per Haisco Pharmaceutical Group Co., Ltd. (002653)
Utile nel Jun 2026 TTM: $144.70M
Secondo gli ultimi rapporti finanziari di Haisco Pharmaceutical Group Co., Ltd., gli utili attuali della società sono $144.70M. Nel 2023, la società ha registrato un utile di $42.74M, una diminuzione rispetto a agli utili del 2022, che erano di $53.15M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Haisco Pharmaceutical Group Co., Ltd. dal 2008 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $144.70M | 128.15% |
| 2024 | $63.43M | 48.41% |
| 2023 | $42.74M | -19.59% |
| 2022 | $53.15M | -33.86% |
| 2021 | $80.36M | -23.86% |
| 2020 | $105.54M | 34.49% |
| 2019 | $78.47M | 67.09% |
| 2018 | $46.96M | 18.07% |
| 2017 | $39.78M | -42.90% |
| 2016 | $69.65M | 8.93% |
| 2015 | $63.94M | -21.50% |
| 2014 | $81.46M | -13.14% |
| 2013 | $93.78M | 21.75% |
| 2012 | $77.03M | 31.46% |
| 2011 | $58.59M | 6.29% |
| 2010 | $55.13M | 19.25% |
| 2009 | $46.23M | 45.27% |
| 2008 | $31.82M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 3,545.32% |
US
|
|
| $-3.09B | -2,233.33% |
US
|
|
| $-4.02B | -2,875.47% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,248.04% |
NL
|
